JP5680823B2 - スクレロスチンエピトープ - Google Patents

スクレロスチンエピトープ Download PDF

Info

Publication number
JP5680823B2
JP5680823B2 JP2008510081A JP2008510081A JP5680823B2 JP 5680823 B2 JP5680823 B2 JP 5680823B2 JP 2008510081 A JP2008510081 A JP 2008510081A JP 2008510081 A JP2008510081 A JP 2008510081A JP 5680823 B2 JP5680823 B2 JP 5680823B2
Authority
JP
Japan
Prior art keywords
seq
cdr
sequence
antibody
sclerostin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008510081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009500296A (ja
Inventor
セン ル，シェン
セン ル，シェン
パツティー，クリストファー
キム ロビンソン，マーティン
キム ロビンソン，マーティン
ジェイムス ヘンリー，アリステア
ジェイムス ヘンリー，アリステア
スー ホフマン，ケリー
スー ホフマン，ケリー
レイサム，ジョン
ローソン，アラステア
ウィンクラー，デヴィッド
ジョージ ウィンターズ，アーロン
ジョージ ウィンターズ，アーロン
Original Assignee
アムジエン・インコーポレーテツド
ユーシービー ファーマ ソシエテ アノニム
ユーシービー ファーマ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36956127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5680823(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アムジエン・インコーポレーテツド, ユーシービー ファーマ ソシエテ アノニム, ユーシービー ファーマ ソシエテ アノニム filed Critical アムジエン・インコーポレーテツド
Publication of JP2009500296A publication Critical patent/JP2009500296A/ja
Application granted granted Critical
Publication of JP5680823B2 publication Critical patent/JP5680823B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Table Devices Or Equipment (AREA)
JP2008510081A 2005-05-03 2006-04-28 スクレロスチンエピトープ Active JP5680823B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US67758305P 2005-05-03 2005-05-03
US60/677,583 2005-05-03
US77684706P 2006-02-24 2006-02-24
US60/776,847 2006-02-24
US78224406P 2006-03-13 2006-03-13
US60/782,244 2006-03-13
US79264506P 2006-04-17 2006-04-17
US60/792,645 2006-04-17
US11/410,540 US8003108B2 (en) 2005-05-03 2006-04-25 Sclerostin epitopes
US11/410,540 2006-04-25
PCT/US2006/016345 WO2006119062A2 (en) 2005-05-03 2006-04-28 Sclerostin epitopes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014095921A Division JP2014177470A (ja) 2005-05-03 2014-05-07 スクレロスチンエピトープ

Publications (2)

Publication Number Publication Date
JP2009500296A JP2009500296A (ja) 2009-01-08
JP5680823B2 true JP5680823B2 (ja) 2015-03-04

Family

ID=36956127

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2008510081A Active JP5680823B2 (ja) 2005-05-03 2006-04-28 スクレロスチンエピトープ
JP2014095921A Pending JP2014177470A (ja) 2005-05-03 2014-05-07 スクレロスチンエピトープ
JP2015192869A Active JP6158268B2 (ja) 2005-05-03 2015-09-30 スクレロスチンエピトープ
JP2017031654A Pending JP2017128583A (ja) 2005-05-03 2017-02-23 スクレロスチンエピトープ
JP2018147689A Active JP6858733B2 (ja) 2005-05-03 2018-08-06 スクレロスチンエピトープ
JP2020081948A Active JP7010994B2 (ja) 2005-05-03 2020-05-07 スクレロスチンエピトープ
JP2021195517A Active JP7361086B2 (ja) 2005-05-03 2021-12-01 スクレロスチンエピトープ

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2014095921A Pending JP2014177470A (ja) 2005-05-03 2014-05-07 スクレロスチンエピトープ
JP2015192869A Active JP6158268B2 (ja) 2005-05-03 2015-09-30 スクレロスチンエピトープ
JP2017031654A Pending JP2017128583A (ja) 2005-05-03 2017-02-23 スクレロスチンエピトープ
JP2018147689A Active JP6858733B2 (ja) 2005-05-03 2018-08-06 スクレロスチンエピトープ
JP2020081948A Active JP7010994B2 (ja) 2005-05-03 2020-05-07 スクレロスチンエピトープ
JP2021195517A Active JP7361086B2 (ja) 2005-05-03 2021-12-01 スクレロスチンエピトープ

Country Status (17)

Country Link
US (3) US8003108B2 (Direct)
EP (6) EP1891100A2 (Direct)
JP (7) JP5680823B2 (Direct)
CA (1) CA2607276C (Direct)
CY (2) CY1118977T1 (Direct)
DK (2) DK2301961T4 (Direct)
ES (5) ES2901698T3 (Direct)
FI (2) FI2301961T4 (Direct)
HR (2) HRP20170514T4 (Direct)
HU (2) HUE033718T2 (Direct)
LT (2) LT2251351T (Direct)
MX (1) MX348432B (Direct)
MY (1) MY174493A (Direct)
PL (2) PL2251351T5 (Direct)
PT (2) PT2251351T (Direct)
SI (2) SI2251351T2 (Direct)
WO (1) WO2006119062A2 (Direct)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1133558E (pt) 1998-11-27 2007-01-31 Ucb Sa Composições e métodos para aumentar a mineralização óssea
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) * 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
NZ544618A (en) * 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US8883162B2 (en) 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US20100226884A1 (en) * 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
US9862770B2 (en) 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
RU2511406C2 (ru) 2006-06-08 2014-04-10 Чугаи Сейяку Кабусики Кайся Профилактическое или лекарственное средство для воспалительного заболевания
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2144613B1 (en) 2006-12-29 2018-03-21 OstéoQC Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
WO2008101234A2 (en) * 2007-02-16 2008-08-21 Sloan-Kettering Institute For Cancer Research Anti ganglioside gd3 antibodies and uses thereof
JP2010524846A (ja) * 2007-03-20 2010-07-22 イーライ リリー アンド カンパニー 抗スクレロスチン抗体
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
KR102467302B1 (ko) 2007-09-26 2022-11-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
ES2663077T3 (es) 2007-11-02 2018-04-11 Novartis Ag Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6)
BRPI0821145B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido
KR101840994B1 (ko) 2007-12-05 2018-03-21 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
CN101896201A (zh) * 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
AU2009288354A1 (en) * 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP3674317B1 (en) 2009-03-19 2024-12-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
PL2896404T3 (pl) * 2009-06-04 2017-12-29 Novartis Ag Sposoby identyfikacji miejsc koniugacji IgG
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US20120244147A1 (en) * 2009-08-17 2012-09-27 Theuer Charles P Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
IN2012DN05101A (Direct) * 2010-01-19 2015-10-23 Immunomedics Inc
SG185035A1 (en) * 2010-05-04 2012-11-29 Five Prime Therapeutics Inc Antibodies that bind csf1r
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
MX362591B (es) 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
MX2013010011A (es) * 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
EA029956B1 (ru) 2011-03-25 2018-06-29 Эмджен Инк. Кристаллы антител против склеростина и составы на их основе
PL3404041T3 (pl) 2011-04-19 2020-12-14 Amgen Inc. Sposób leczenia osteoporozy
JP2014515759A (ja) 2011-04-29 2014-07-03 ノバルティス アーゲー 扁平上皮がんを治療する方法関連出願
WO2013019954A1 (en) 2011-08-04 2013-02-07 Amgen Inc. Method for treating bone gap defects
SG10201509629QA (en) 2011-12-28 2015-12-30 Amgen Inc Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
JP6770312B2 (ja) * 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
US10431325B2 (en) 2012-08-03 2019-10-01 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
SMT201900339T1 (it) 2013-02-22 2019-07-11 Medimmune Ltd Coniugati anticorpo anti-dll3/pbd e loro usi
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2015031698A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Site-specific antibody conjugation methods and compositions
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US11813328B2 (en) 2014-10-23 2023-11-14 Amgen Inc. Methods for reducing the viscosity of liquid pharmaceutical formulations comprising therapeutic proteins
WO2016069727A1 (en) 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
WO2016106180A1 (en) 2014-12-22 2016-06-30 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6755513B2 (ja) * 2015-03-13 2020-09-16 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． 抗スクレロスチン抗体、その抗原結合フラグメントおよびその医薬用途
PL3283527T3 (pl) 2015-04-13 2021-06-14 Five Prime Therapeutics, Inc. Leczenie skojarzone nowotworów
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
EP4650370A2 (en) 2015-04-14 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
TWI715587B (zh) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CL2016000164A1 (es) * 2016-01-21 2016-07-29 Pontificia Universidad Católica De Chile Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv.
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EA039540B1 (ru) * 2016-03-25 2022-02-08 Онкомед Фармасьютикалс, Инк. Связывающие tigit агенты и варианты их применения
JOP20180117B1 (ar) 2016-07-12 2022-03-14 H Lundbeck As أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
US20190185556A1 (en) 2016-08-08 2019-06-20 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
EP3548071A4 (en) 2016-11-30 2020-07-15 OncoMed Pharmaceuticals, Inc. CANCER TREATMENT METHODS INCLUDING TIGIT BINDING AGENTS
BR112019012731A2 (pt) 2016-12-21 2019-11-26 Mereo Biopharma 3 Limited uso de anticorpos antiesclerostina no tratamento de osteogênese imperfeita
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EP3574010A4 (en) 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTINE ANTIBODIES AND METHODS OF USE
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
AU2018258676B2 (en) 2017-04-28 2024-09-19 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
JP7237022B2 (ja) 2017-08-01 2023-03-10 アムジエン・インコーポレーテツド 質量分析法による分析用ポリペプチド試料のリアルタイム調製のためのシステム及び方法
US12025618B2 (en) 2017-08-01 2024-07-02 Amgen Inc. Systems and methods for performing a real-time glycan assay of a sample
EP3681535A1 (en) 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
US12405275B2 (en) 2018-03-13 2025-09-02 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
US12429405B2 (en) 2018-03-13 2025-09-30 Amgen Inc. Sequential digestion of polypeptides for mass spectrometric analysis
US11466079B2 (en) 2018-03-30 2022-10-11 Amgen Inc. C-terminal antibody variants
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
JP7425041B2 (ja) 2018-08-10 2024-01-30 アムジエン・インコーポレーテツド 抗体医薬製剤を作製する方法
JP7769544B2 (ja) 2018-12-14 2025-11-13 アムジエン・インコーポレーテツド 勾配によるタンパク質濃度定量を伴う使用のためのシステム適合性方法
EP3924083B1 (en) 2019-02-14 2024-05-15 Amgen Inc. Systems and methods for preparing a sample and performing a real-time assay of the sample
ES2997116T3 (en) 2019-02-20 2025-02-14 Amgen Inc Methods of determining protein stability
WO2020180967A1 (en) 2019-03-04 2020-09-10 Amgen Inc. In vivo reversibility of high molecular weight species
WO2020198538A1 (en) 2019-03-27 2020-10-01 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
MX2021014733A (es) 2019-06-05 2022-04-06 Amgen Inc Metodos de identificacion de atributos de proteinas terapeuticas.
EP4013786A1 (en) 2019-08-12 2022-06-22 Amgen Inc. Anti-sclerostin antibody formulations
US12497446B2 (en) 2019-08-13 2025-12-16 The Feinstein Institutes For Medical Research Tetranectin-targeting monoclonal antibodies to fight against lethal sepsis and other pathologies
TWI860426B (zh) 2019-11-20 2024-11-01 日商中外製藥股份有限公司 含有抗體之製劑
CA3195365A1 (en) 2020-09-18 2022-03-24 Amgen Inc. Methods of processing a sample for peptide mapping analysis
JP2023549113A (ja) 2020-11-05 2023-11-22 アムジエン・インコーポレーテツド タンパク質を処理するための材料及び方法
EP4430174A1 (en) 2021-11-09 2024-09-18 Amgen Inc. Production of therapeutic proteins
CN121311767A (zh) 2023-06-14 2026-01-09 百时美施贵宝公司 糖蛋白的近实时唾液酸定量
AR133302A1 (es) 2023-07-19 2025-09-17 Amgen Inc Métodos de preparación de amortiguador para una formulación de proteína terapéutica
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein
WO2025255028A1 (en) 2024-06-03 2025-12-11 Amgen Inc. High-throughput liquid chromatography-mass spectrometry-based peptide mapping

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32011A (en) 1861-04-09 Coffee-pot
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5837456A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
AU662304B2 (en) 1990-10-22 1995-08-31 Fox Chase Cancer Center DNA construct for providing RNA therapy
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
CA2164505A1 (en) 1993-06-07 1994-12-22 Phillip W. Berman Hiv envelope polypeptides
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
JPH10511840A (ja) 1994-04-29 1998-11-17 クリエイティブ バイオモレキュールズ，インコーポレイテッド 形態形成タンパク質特異細胞表面レセプターおよびその使用
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2220912A1 (en) 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
WO1997044461A2 (en) 1996-05-22 1997-11-27 Novopharm Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
WO1999006554A2 (en) 1997-08-01 1999-02-11 Genset 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
PT1133558E (pt) 1998-11-27 2007-01-31 Ucb Sa Composições e métodos para aumentar a mineralização óssea
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU4851900A (en) 1999-06-09 2000-12-28 Genentech Inc. Compositions and methods for the treatment of tumor
AU4196801A (en) 2000-03-02 2001-09-12 Amgen Inc Chordin-like-2 molecules and uses thereof
EP1290169A2 (en) 2000-06-01 2003-03-12 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
JP2004520005A (ja) 2000-06-19 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー オステオレビン遺伝子多型性
CA2421056A1 (en) 2000-09-01 2002-03-28 Genentech, Inc. A polypeptide for use as a diagnostic marker for the presence of colon tumours
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
NZ533051A (en) 2001-12-06 2006-10-27 Biocontrol Systems Inc Sample collection and testing system
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
JP4662714B2 (ja) 2002-03-01 2011-03-30 セルテック アール アンド ディー インコーポレイテッド 骨密度を増減させる方法
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
FR2838379B1 (fr) 2002-04-12 2005-06-24 Valeo Climatisation Dispositif de purification de l'air de l'habitacle d'un vehicule automobile
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
EP1572122A4 (en) 2002-11-01 2008-04-09 Us Gov Health & Human Serv METHOD FOR PREVENTING INFECTIONS OF BIOTERRORISM AGENTS WITH IMMUNOSTIMULATING CPG OLIGONUCLEOTIDES
DE10255152A1 (de) 2002-11-26 2004-06-03 Von Langen Ursula Lang Schadstoffsauger
FI115753B (fi) 2002-11-29 2005-07-15 Paloheimo Raija Menetelmä ja sovitelma kahvijuomien valmistamiseksi
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
ES2379689T3 (es) 2003-03-14 2012-04-30 Ucb Manufacturing, Inc. A Company Incorporated Under The Laws Of The State Of Delaware Complejo de esclerostina y nogina o cordina, y agentes que modulan la formación de dicho complejo
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20100015665A1 (en) 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
MX2009008096A (es) 2007-02-02 2009-08-07 Novartis Ag Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos.
JP2010524846A (ja) 2007-03-20 2010-07-22 イーライ リリー アンド カンパニー 抗スクレロスチン抗体
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
ES2663077T3 (es) 2007-11-02 2018-04-11 Novartis Ag Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6)
CN101896201A (zh) 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法

Also Published As

Publication number Publication date
EP2295448B1 (en) 2017-01-18
PL2251351T3 (pl) 2017-07-31
EP2301961B2 (en) 2023-07-12
US20110305702A1 (en) 2011-12-15
HRP20170514T4 (hr) 2023-11-10
EP2251351A1 (en) 2010-11-17
HUE033718T2 (en) 2017-12-28
FI2251351T4 (fi) 2023-10-20
PL2301961T5 (pl) 2023-11-13
US8715663B2 (en) 2014-05-06
EP2298800B9 (en) 2024-03-27
ES2616985T3 (es) 2017-06-15
SI2301961T1 (sl) 2017-06-30
DK2251351T3 (en) 2017-04-03
EP2295448A1 (en) 2011-03-16
CY1118977T1 (el) 2018-01-10
DK2301961T4 (da) 2023-09-25
US8003108B2 (en) 2011-08-23
EP2345668B1 (en) 2021-09-22
JP2022024162A (ja) 2022-02-08
HRP20170679T4 (hr) 2023-10-13
EP2298800B2 (en) 2023-05-31
EP2295448B2 (en) 2023-05-31
HRP20170679T1 (hr) 2017-07-14
EP2301961A1 (en) 2011-03-30
ES2901698T3 (es) 2022-03-23
JP6858733B2 (ja) 2021-04-14
JP2016011307A (ja) 2016-01-21
ES2619709T3 (es) 2017-06-26
ES2620684T5 (es) 2023-11-16
PL2301961T3 (pl) 2017-10-31
JP7010994B2 (ja) 2022-02-10
CA2607276A1 (en) 2006-11-09
SI2251351T1 (sl) 2017-06-30
PL2251351T5 (pl) 2023-12-04
WO2006119062A3 (en) 2007-06-28
JP2020122011A (ja) 2020-08-13
US9353174B2 (en) 2016-05-31
MY174493A (en) 2020-04-23
JP2009500296A (ja) 2009-01-08
US20140248666A1 (en) 2014-09-04
JP6158268B2 (ja) 2017-07-05
US20070072797A1 (en) 2007-03-29
JP2014177470A (ja) 2014-09-25
DK2301961T3 (en) 2017-05-15
FI2301961T4 (fi) 2023-10-02
EP2251351B1 (en) 2017-01-04
EP2298800A1 (en) 2011-03-23
CY1119127T1 (el) 2018-02-14
EP1891100A2 (en) 2008-02-27
LT2251351T (lt) 2017-04-25
WO2006119062A2 (en) 2006-11-09
ES2620684T3 (es) 2017-06-29
JP2018188467A (ja) 2018-11-29
LT2301961T (lt) 2017-06-12
EP2251351B2 (en) 2023-07-26
DK2251351T4 (da) 2023-10-23
MX348432B (es) 2017-06-05
EP2345668A1 (en) 2011-07-20
ES2624643T3 (es) 2017-07-17
EP2301961B1 (en) 2017-02-22
ES2624643T5 (es) 2023-12-26
EP2298800B1 (en) 2016-11-30
JP7361086B2 (ja) 2023-10-13
PT2251351T (pt) 2017-03-17
EP2301961B9 (en) 2023-12-13
HRP20170514T1 (hr) 2017-06-02
SI2301961T2 (sl) 2023-10-30
ES2619709T5 (es) 2024-02-22
SI2251351T2 (sl) 2023-11-30
CA2607276C (en) 2016-08-30
PT2301961T (pt) 2017-05-22
JP2017128583A (ja) 2017-07-27
HUE032092T2 (en) 2017-08-28
ES2616985T5 (es) 2023-11-16

Similar Documents

Publication Publication Date Title
JP7361086B2 (ja) スクレロスチンエピトープ
JP5789652B2 (ja) スクレロスチン結合作用物質
HK1152954A (en) Sclerostin binding agents
HK1153762B (en) Sclerostin epitopes
HK1149021B (en) Sclerostin epitopes
HK1149276A (en) Sclerostin binding antibodies
HK1149771B (en) Sclerostin epitopes
HK1145330B (en) Sclerostin epitopes
HK1149771A (en) Sclerostin epitopes
HK1153762A (en) Sclerostin epitopes
HK1151544A (en) Sclerostin binding agents
HK1146068A (en) Sclerostin binding antibody
HK1149021A (en) Sclerostin epitopes
HK1149276B (en) Sclerostin binding antibodies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140619

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150108

R150 Certificate of patent or registration of utility model

Ref document number: 5680823

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250